Wachtell and Cravath lead for Pfizer/Mylan merger

Pfizer and Mylan have tapped Wachtell Lipton Rosen & Katz and Cravath Swaine & Moore, respectively, to oversee the proposed combination of Pfizer’s Upjohn and generic drugmaker Mylan.

Get unlimited access to all Global Competition Review content